New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025...
Design Therapeutics to Webcast Fourth Quarter & Full Year 2023 Financial Results
? Design Therapeutics chairman Pratik Shah has succeeded João Siffert as CEO while teasing a “strategic realignment” that won’t be revealed until early 2024, according to its Q3 report. Design does elaborate on the status of its cash runway, which is projected to keep the lights on “through 2028” as a result of the changes. Shah has chaired the board since 2017 and is connected to two Laura Shawver biotechs as the ex-chairman of Synthorx — purchased by Sanofi — and the current chairman at ARS Pharmaceuticals, which merged with Shawver-led Silverback Therapeutics last year. Siffert took the top spot at Design in October 2020 after resigning as CEO, head of R&D and CMO at Abeona Therapeutics.
Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 ...
Design Therapeutics said Tuesday morning that it was planning to reformulate its Friedreich’s ataxia drug following injection site reactions in a Phase I study.
Design Therapeutics is living up to its name. After seeing adverse events in its phase 1 rare disease trial, the biotech has redesigned the formulation to counter the problem—but the developments have set the program back years and triggered a 60% stock drop.
DT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation...
Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels in Skeletal Muscle Company Expects to Resume a Multiple Dose...
CARLSBAD, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results